Literature DB >> 7308276

Correlation of serum and saliva theophylline concentration after administration of a sustained release preparation.

J H Jonkman, G H Koëter, R Schoenmaker, K de Vries, J E Greving, R A de Zeeuw.   

Abstract

The correlation between serum and saliva levels of theophylline was investigated in seven healthy volunteers after multiple dose administration of a low dose (300 mg/day) and a high dose (900 mg/day) of a sustained release theophylline preparation (Theo-Dur). Tablets were taken for five days, at 8 a. m. and 8 p. m. and a last dose was taken on Day 6 at 8 a. m. Fourteen serum and saliva samples were collected simultaneously during the dosing period and for up to 32 h after the last dose. On the 300 mg/day regimen the level in saliva was 55.3% of the serum level, with an overall variability of 6.7% and an intrasubject variability of 10.5%. After 900 mg/day, the saliva concentration was 55.5% of the serum concentration, with an overall variability of 7.6% and an intrasubject variability of 12.7%. A good correlation was found between both determinations (r = 0.99), which suggests that saliva levels could be used to monitor theophylline after administration of a sustained release tablet.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7308276     DOI: 10.1007/bf00554670

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Reliability of salivary theophylline as a guide to plasma theophylline levels.

Authors:  S P Galant; S A Gillman; L H Cummins; P P Kozak; J J Orcutt
Journal:  Am J Dis Child       Date:  1977-09

2.  Indirect plasma-theophylline monitoring in asthmatic children by determination of theophylline concentration in saliva.

Authors:  G Levy; E F Ellis; R Koysooko
Journal:  Pediatrics       Date:  1974-06       Impact factor: 7.124

3.  Relationship between theophylline concentration in plasma and saliva of man.

Authors:  R Koysooko; E F Ellis; G Levy
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

4.  [Drug concentrations in plasma and saliva--physiologic and pharmacokinetic considerations].

Authors:  J Posti
Journal:  Pharm Acta Helv       Date:  1979

5.  A rapidly dissolving theophylline tablet.

Authors:  A Cohen; C Johnson; O Re
Journal:  Curr Ther Res Clin Exp       Date:  1975-05

6.  The relation of product formulation to absorption of oral theophylline.

Authors:  M Weinberger; L Hendeles; L Bighley
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

7.  Plasma-saliva ratio of theophylline following oral theophylline derivatives [proceedings].

Authors:  S Boobis; P W Trembath
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

8.  Unpredictability of theophylline saliva measurements in chronic obstructive pulmonary disease.

Authors:  L Hendeles; S Burkey; L Bighley; R Richardson
Journal:  J Allergy Clin Immunol       Date:  1977-12       Impact factor: 10.793

9.  Pharmacokinetics of theophylline in hepatic disease.

Authors:  A Mangione; T E Imhoff; R V Lee; L Y Shum; W J Jusko
Journal:  Chest       Date:  1978-05       Impact factor: 9.410

10.  Disposition and clinical pharmacokinetics of microcrystalline theophylline.

Authors:  J H Jonkman; W C Berg; R Schoenmaker; R A de Zeeuw; J E Greving; N G Orie
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

View more
  4 in total

Review 1.  Theophylline.

Authors:  E F Ellis
Journal:  Clin Rev Allergy       Date:  1983-03

2.  Pharmacokinetics of sustained release theophylline in low and high multidose regimens.

Authors:  G H Koëter; J H Jonkman; K de Vries; R Schoenmaker; J E Greving; R A de Zeeuw
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

3.  Reproducibility of saliva and plasma theophylline levels following single dose administration of two sustained release preparations.

Authors:  A H Jackson; C Edwards; A S Cope; R A Stockley; R Purkiss
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

4.  Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients.

Authors:  K Takagi; K Yamaki; M Nadai; T Kuzuya; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.